Enrolment halted in key Avastin Phase III adjuvant breast cancer trial
This article was originally published in Scrip
Executive Summary
Enrolment in a key pivotal Phase III trial testing Roche (Genentech)'s Avastin (bevacizumab) in adjuvant breast cancer has been suspended because the threshold of numbers of cases of congestive heart failure (CHF) had been met, highlighting the higher safety hurdle that needs to be demonstrated in the adjuvant disease setting. The trial's Data Safety Monitoring Board (DSMB) will decide if and when to resume enrolment, which will be a major decision for Avastin’s future in adjuvant breast cancer.